Dynamically Tumor-targeted Nanopharmaceuticals: the Next Chapter in the Fight Against Cancer
It has been more than 40 years since cancer prevention and treatment initiatives were placed atop the national agenda with the signing of the National Cancer Act and the creation of the National Cancer Institute. Since that time, extensive research and development has led to significant medical breakthroughs for a number of different types of cancer. However, in many other cancer types—such as lung cancer—survival rates remain alarmingly low.
Personalized medicines have proven the value of tumor-targeting, and have laid a strong foundation for the next chapter in the fight against cancer. ‘Smart bombs’ such as antibody-drug conjugates (commonly referred to as ADCs) and nanopharmaceuticals that deliver potent anti-cancer agents to the tumors while sparing healthy tissue are the next chapter in the fight against cancer because they give patients hope for longer overall survival and better quality of life, especially when used in combination.
Tumor-targeted Nanopharmaceuticals: Best of Both Worlds
Much like ADCs, nanopharmaceuticals are ‘smart bombs’ that merge the best attributes of traditional chemotherapy and personalized medicines, while mitigating the disadvantages associated with these types of treatments.
In pre-clinical and clinical studies, our nanopharmaceuticals have been well tolerated and are therefore readily combinable with other cancer therapies, including ‘personalized medicines.’ These advantages should allow physicians to treat patients with drug cocktails that are more effective and less susceptible to drug resistance than monotherapies. Cocktails of highly potent and tolerable cancer drugs could turn cancer into a manageable chronic disease in much the same way that modern science produced drug cocktails that have turned HIV from a universally fatal disease into a manageable chronic disease.